{'52WeekChange': 0.052197695,
 'SandP52WeekChange': 0.0644362,
 'address1': '40 Erie Street',
 'address2': 'Suite 130',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 19.98,
 'askSize': 1300,
 'averageDailyVolume10Day': 667662,
 'averageVolume': 1003612,
 'averageVolume10days': 667662,
 'beta': 1.734716,
 'beta3Year': None,
 'bid': 18.78,
 'bidSize': 1400,
 'bookValue': 4.896,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 19.36,
 'dayLow': 18.81,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.905,
 'enterpriseToRevenue': 16.629,
 'enterpriseValue': 758039168,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 21.419144,
 'fiftyTwoWeekHigh': 25.56,
 'fiftyTwoWeekLow': 9.18,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 45139292,
 'forwardEps': -2.9,
 'forwardPE': -6.603448,
 'fromCurrency': None,
 'fullTimeEmployees': 270,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.19017,
 'heldPercentInstitutions': 0.76405,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/intelliatx.com',
 'longBusinessSummary': 'Intellia Therapeutics, Inc., a genome editing '
                        'company, focuses on the development of therapeutics. '
                        'It utilizes a biological tool known as the Clustered, '
                        'Regularly Interspaced Short Palindromic '
                        'Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The '
                        'company develops in vivo programs focusing on liver '
                        'diseases, including transthyretin amyloidosis and '
                        'hereditary angioedema, as well as other research '
                        'programs comprising primary hyperoxaluria Type 1, '
                        'alpha-1 antitrypsin deficiency, and Hemophilia B. Its '
                        'ex vivo pipeline includes proprietary programs '
                        'focused on developing engineered cell therapies to '
                        'treat various oncological and autoimmune diseases; '
                        'partnered programs focused on chimeric antigen '
                        'receptor T cells and hematopoietic stem cells; and '
                        'acute myeloid leukemia. Intellia Therapeutics, Inc. '
                        'has license and collaboration agreements with '
                        'Novartis Institutes for BioMedical Research, Inc.; '
                        'Regeneron Pharmaceuticals, Inc.; Ospedale San '
                        'Raffaele; and GEMoaB Monoconals GmbH. The company was '
                        'formerly known as AZRN, Inc. and changed its name to '
                        'Intellia Therapeutics, Inc. in July 2014. Intellia '
                        'Therapeutics, Inc. was founded in 2014 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Intellia Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1123120640,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_277799796',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -109399000,
 'nextFiscalYearEnd': 1640908800,
 'open': 19.2135,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.25,
 'phone': '857 285 6200',
 'previousClose': 19.65,
 'priceHint': 2,
 'priceToBook': 3.9113562,
 'priceToSalesTrailing12Months': 24.637403,
 'profitMargins': -2.3998399,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 19.36,
 'regularMarketDayLow': 18.81,
 'regularMarketOpen': 19.2135,
 'regularMarketPreviousClose': 19.65,
 'regularMarketPrice': 19.2135,
 'regularMarketVolume': 528936,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 58648600,
 'sharesPercentSharesOut': 0.1906,
 'sharesShort': 11179379,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 10810095,
 'shortName': 'Intellia Therapeutics, Inc.',
 'shortPercentOfFloat': 0.26680002,
 'shortRatio': 8.76,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'NTLA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.253,
 'twoHundredDayAverage': 16.097483,
 'volume': 528936,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.intelliatx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}